Adage Capital Partners
IRWD icon

Adage Capital Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Adage Capital Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,511,789
Closed -$17.3M – 917
2023
Q4 		$17.3M Sell
1,511,789
-950,511
-39% -$9.4M 0.04% 463
2023
Q3 		$23.7M Buy
2,462,300
+1,518,500
+161% +$14.9M 0.05% 344
2023
Q2 		$10M Buy
+943,800
New +$10.1M 0.02% 571
2020
Q2 		– Sell
-1,375,000
Closed -$13.9M – 771
2020
Q1 		$13.9M Hold
1,375,000
– – 0.04% 402
2019
Q4 		$18.3M Buy
1,375,000
+700,000
+104% +$7.72M 0.04% 403
2019
Q3 		$5.79M Hold
675,000
– – 0.01% 612
2019
Q2 		$7.38M Sell
675,000
-1,563,750
-70% -$17.5M 0.02% 563
2019
Q1 		$25.4M Hold
2,238,750
– – 0.06% 328
2018
Q4 		$19.4M Sell
2,238,750
-597,000
-21% -$6.85M 0.05% 338
2018
Q3 		$43.8M Buy
2,835,750
+597,000
+27% +$9.44M 0.1% 247
2018
Q2 		$35.9M Hold
2,238,750
– – 0.08% 276
2018
Q1 		$28.9M Sell
2,238,750
-10,499
-0.5% -$131K 0.07% 321
2017
Q4 		$28.2M Sell
2,249,249
-1,213,351
-35% -$15.8M 0.06% 335
2017
Q3 		$45.7M Sell
3,462,600
-626,850
-15% -$8.63M 0.11% 241
2017
Q2 		$64.7M Sell
4,089,450
-3,014,850
-42% -$43.8M 0.16% 177
2017
Q1 		$102M Hold
7,104,300
– – 0.26% 102
2016
Q4 		$91M Buy
7,104,300
+627,328
+10% +$7.92M 0.25% 111
2016
Q3 		$86.1M Buy
6,476,972
+4,208,372
+186% +$49.2M 0.24% 113
2016
Q2 		$24.8M Buy
2,268,600
+1,194,000
+111% +$11.7M 0.07% 326
2016
Q1 		$9.85M Buy
+1,074,600
New +$8.86M 0.03% 523
2014
Q4 		– Sell
-646,642
Closed -$7.02M – 740
2014
Q3 		$7.02M Sell
646,642
-747,450
-54% -$8.56M 0.02% 582
2014
Q2 		$17.9M Buy
1,394,092
+871,658
+167% +$9.48M 0.05% 417
2014
Q1 		$5.39M Sell
522,434
-481,375
-48% -$5.41M 0.01% 581
2013
Q4 		$9.76M Sell
1,003,809
-1,015,139
-50% -$9.11M 0.03% 520
2013
Q3 		$20M Hold
2,018,948
– – 0.06% 377
2013
Q2 		$16.8M Buy
+2,018,948
New +$24.5M 0.05% 398

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Adage Capital Partners's IRWD Position: Q1 2024 in Review

Adage Capital Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2024, closing a stake of 1,511,789 shares — an estimated $17.3M sold.

Adage Capital Partners first reported a position in IRWD in Q2 2013 and held it in 26 quarters. The position peaked at $102M in Q1 2017. 261 funds tracked by Wall St. Rank hold IRWD as of Q1 2024.

  • Adage Capital Partners reported no remaining Ironwood Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 1,511,789 Ironwood Pharmaceuticals shares in Q1 2024, an estimated $17.3M.
  • Adage Capital Partners first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Adage Capital Partners's Ironwood Pharmaceuticals position peaked at $102M in Q1 2017.
  • 261 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.